Ex-Neuralink Chief Warns China Won First BCI Race
Key insights
- China approved the world's first commercially available brain-computer interface, technology that decodes brain activity to control physical actions or devices.
- Beijing designated BCIs a national strategic priority, giving Chinese developers regulatory speed advantages over US competitors still waiting for approval.
- Science Corp, Hodak's current company, raised $230 million in March to commercialize retinal implant and organ-viability technology.
Why this matters
China's approval of the first commercial BCI shifts the competitive race from who has the best science to who has the fastest path to market. US BCI and medical device founders now face a structural disadvantage in clinical-data accumulation and first-mover scale that regulatory reform, not additional R&D investment, would need to fix. Hodak's cancer-care-in-Shanghai scenario maps a trajectory already visible in medical tourism, where patients seeking cutting-edge treatment go wherever approvals and costs align first.
Summary
Former Neuralink president Max Hodak says China's approval of the first commercially available brain-computer interface puts the US dangerously behind.
At the Semafor Tech summit, Hodak warned that without regulatory reform, wealthy Americans may need to travel to Shanghai for cancer care within a decade. China has designated BCIs a national priority, with streamlined regulatory systems enabling faster commercialization than the US approach allows.
Essentially: (Science Corp, Neuralink) Hodak's Science Corp raised $230 million in March for retinal implants and organ-viability technology, but his warning spans the entire US health-tech sector.
- First commercial BCI approved in China, decoding brain signals to control physical actions.
- BCIs are a Chinese national strategic priority.
- Hodak: 'one of the three or four major plot lines of the next decade.'
Regulatory speed now determines who leads global neurotechnology.
Potential risks and opportunities
Risks
- US BCI developers awaiting regulatory approval face compounding disadvantage as China's approved product accumulates real-world clinical data and iterates faster without the same approval delays.
- Wealthy American patients seeking advanced neurology or oncology treatments could shift demand to Chinese institutions within Hodak's projected decade, reducing US clinical trial enrollment and hospital revenue.
- Science Corp's $230 million raise faces execution pressure if US regulatory timelines remain slow while Chinese competitors build commercial scale in the already-approved BCI market.
Opportunities
- US BCI developers gain concrete leverage for faster regulatory dialogue, using China's first commercial BCI approval as a competitive benchmark in policy and agency conversations.
- Science Corp's retinal implant and organ-viability products could pursue regulatory approval in markets outside the US with faster pathways, building clinical data and revenue ahead of US clearance.
- Policy-focused health-tech investors and advocacy groups can use China's commercial BCI approval as a catalyst for US legislative action on medical device regulatory reform.
What we don't know yet
- Which specific Chinese company or institution holds the commercial BCI approval, and what clinical evidence supported it: not disclosed in the article.
- Whether any US BCI developers have active regulatory timelines that would close the competitive gap Hodak describes within his projected decade.
- What specific US regulatory reforms Hodak is advocating for, beyond the general warning framed by the cancer-care-in-Shanghai scenario.
Originally reported by tech.yahoo.com
Read the original article →Original headline: China Approves World's First Commercial Brain-Computer Interface; Ex-Neuralink President Warns U.S. Regulatory Gaps Cede Health-Tech Lead to Shanghai